Meeting
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Autoimmune toxicities with anti-PD-1 treatment of metastatic melanoma in predominantly older patients: A single institutional experience.
Authors
Harsh V Parmar
University of Connecticut, Farmington, CT
Harsh V Parmar, Phil Kerr, Christina Elizabeth Stevenson, Sophie Masternak, Upendra P. Hegde
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Citation
J Clin Oncol 37, 2019 (suppl 8; abstr 144)
DOI
10.1200/JCO.2019.37.8_suppl.144
Abstract #
144
Poster Bd #
G1
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Clinical value of noninvasive biomarkers reflecting a collagen-rich stroma in metastatic melanoma patients treated with anti-PD1 therapy.
First Author: Christina Jensen
Poster
2018 ASCO Annual Meeting
Anti-PD1 antibodies in late elderly advanced melanoma patients: A retrospective multicentre study.
First Author: Francesco De Rosa
Poster
2016 ASCO Annual Meeting
Anti-PD-1 tolerance after severe toxicity with ipilimumab therapy in metastatic melanoma patients.
First Author: Angelique Brunot
Poster
2022 ASCO Annual Meeting
Randomized phase 3 trial of IO102-IO103 plus pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic melanoma.
First Author: Inge Marie Svane